TICAROS

OVERVIEW OF THE COMPANY

Next Generation

Immunotherapy

TICAROS Co.Ltd is a biotech company which develops the next generation immunotherapeutics for cancers.

Recently, alongside with antibody techniques, the immuno-oncology therapies are evolving into novel cellular therapeutics which harbor immune cell therapies and gene therapies together. Especially, the outstanding clinical efficacy of CAR-T cell therapies and the potential for successful TCR-T therapies are leading a new era of cancer therapeutics

TICAROS develops matchless CAR-T and cell therapeutics for cancer treatment, by leveraging accumulated experiences and technologies of the immunologists at Seoul National University, College of Medicine. We hope that these efforts will lead to a novel breakthrough in treatment of not only intractable hematologic malignancies but also of advanced solid tumors.

MISSION

" We create novel therapeutics based on Science "

“We will contribute to human welfare by providing a breakthrough in medicine”

Passion

Intergrity

Creativity

HISTORY

TICAROS:
From Research to Therapeutics

2008~2018

Converter CAR-T

Publication (Blood)

Patent Regi. (KR, US, JP)

TICAROS Est

2018.6월

Partnership

National Cancer Center, Korea
2019~2020

CLIP CAR-T

R&D

Grant

Ministry of SMEs

Ministry of Health & Welfare($2M)

Ministry of Trade, Industry and Energy

Funding

Series A&B $8M

R&D Partnership

SNU College of Medicine
2021

HQ, R&D Center Relocation: Seongsu, Seoul

BAB

Prof. Peter Kash, Ed.D. MBA

CLIP CAR-T

Patent Reg.(KR), PCT App.

Grants

Ministry of SMEs($0.1M)

KDDF Drug Development($1M)

KDDF R&D Funding($1M) / Didimdol

Funding

Series C $22M
2022~2023

IND Approved (ROK)

TC011(Phase I & II)

Grants

KDDF Clinical Trial Funding($1.5M)

Ministry of SMEs($0.1M)

Ministry of Science and ICT(POSTECH)

Presentation

’23 BIO-International

2024

R&D, Business Partnership

Cartherics, City of Hope.

Grants

KDDF New Drug R&D Funding($1M)

Ministry of SMEs($0.5M)

Ministry of Trade, Industry and Energy

Ministry of Health & Welfare: Medical

Global Collaboration($1.5M/yr)

Selected as “Ultra-Gap Company”($0.35M)

Physician-Scientist Joint Research ($1.1M/yr × 5 yrs)

Open Innovation

J&J Innocation – JLABS Korea
Manuscript Published

Nature Communications (Switchable)
2025

National Grant

Full-Lifecycle Immune-Cell Gene

Therapy Technologies ($3.3M);
MFDS Bio-Challenger.

Global K-cell bank library Funding($2.2M)

Manuscript Published

Nature Communications (CLIP CAR)

Awards

Korea Startup Culture Awards, Minister of SMEs and Startups Award

Global Open Innovation, Minister of Health and Welfare Award
2026

IND

Approved (ROK) TC011 – Follicular Lymphoma (Phase II, indication expansion)

Funding

series D $15M

Key members

Kyung Ho Choi

CTO / CTO
- Professor, Seoul National University College of Medicine (Molecular Immunology)
- Chair of the Scientific Committee, Korean Society for Immune Cell and Gene Therapy (KSICGT)
- President-Elect, The Korean Association of Immunologists (KAI)
- Senior Researcher, National Cancer Center (NCC), Korea
- Postdoctoral Fellow, National Institutes of Health (NIH), USA
- M.S., M.D., Ph.D. in Biochemistry, Seoul National University College of Medicine
Jae Won Lee

CEO / COO
- CFO, DiNonA (Antibody Biotechs)
- Vice President (VP), Dimension Investment Advisory
- Managing Director (MD), Dream Technology Investment
- Head of Treasury, HSBC & BNP Paribas Bank
- B.A. and M.S. in Business Administration, Sungkyunkwan Universit
Eun Young Choi

CSO
- Professor, Seoul National University College of Medicine (Immunogenetics)
- Postdoctoral Fellow, The Jackson Laboratory, USA (Immunogenetics)
- B.S., M.S., and Ph.D. in Immunology, Seoul National University College of Natural Sciences
Hyung Bae Park

Director of Research Center
- Visiting Researcher, Cancer Research Institute, Seoul National University
- Assistant Professor, Brain Korea(BK)21 Seoul National University
- Hematologic Malignancy Branch, National Cancer Center
- Ph. D., College of Medicine, Seoul National University (Immunology)
Sun Young Park

CMC Director of Research Center
- Principal Scientist, Samsung Bioepis
- Manager, Healthcare division, SK Telecom
- Ph. D., College of Medicine, Seoul National University (Biochemistry)
Young Ok Kim

Director of Clinical Development Center
- Executive Vice President (EVP) & Head of Clinical Trials, Ensol Biosciences
- Managing Director (MD) / Head of CTM Team, Herings
- Team Lead, PRA Health Sciences
- B.S. in Nursing, Yonsei University
Sung Hoon Jung

Sr Director of Business Management Headquarters
- Managing Director, Woojin Interlogis
- Olympus Korea Business Management
- Samsung SDS Business Management
- B.A., in Economics, Korea University